St. Louis-based MediBeacon completed a clinical study on subjects with impaired kidney function.
Here's what you should know.
1. Biolase conducted the study at Washington University in St. Louis. Researchers measured kidney function in health subjects to those with Stage 4 chronic kidney disease.
2. The company used its Transdermal Glomerular Filtration Rate Monitor. The system employs an optical skin sensor and a fluorescent tracer agent to provide physicians with real-time kidney monitoring.
3. MediBeacon CEO Steve Hanley said, "Completion of our clinical study on patients with impaired kidney function represents an important milestone. "
4. MediBeacon is conducting a multicenter, international study of the monitor in the fourth quarter of 2017.